Introduction
============

Ductal carcinoma *in situ*(DCIS) of the breast represents a heterogeneous group of non-invasive breast tumours commonly detected in women undergoing screening mammography. DCIS is characterised by malignant epithelial cells accumulating in the ducts of the breast without invading through the basement membrane into the surrounding tissue. DCIS accounts for approximately 3% of symptomatic breast malignancies and for approximately 20% of breast malignancies in patients from population-based screening programs \[[@B1]\].

Different histological types of DCIS can be recognised, and a variety of classification systems have been developed \[[@B2]\]. Due to subjective interpretation of the morphology of the lesions, even experienced pathologists differ in their classification of DCIS \[[@B3]\]. Therefore, histological classification of DCIS may not be sufficient, and additional classification approaches could assist pathological classification.

It is assumed that most cases of DCIS will progress to invasive breast cancer. Because this progression may take many years and may not occur within the lifetime of a patient, elucidating the mechanisms of progression from *in situ*lesions to invasive disease and developing diagnostic tests would be of great clinical benefit.

Several models of the evolution of DCIS to invasive cancer have been suggested. One model suggests the linear progression from low-nuclear-grade DCIS to high-nuclear DCIS and the subsequent development of invasive cancer \[[@B4]\]. Based on specific genetic alterations found in the different types of DCIS, a more likely scenario is the evolution of well-, moderately, and poorly differentiated DCIS via distinct pathways. Following this idea, well-differentiated DCIS can give rise to low-grade invasive carcinoma, whereas poorly differentiated DCIS can give rise to high-grade invasive breast cancer \[[@B5],[@B6]\].

Several specific genetic alterations have been found in DCIS. HER2 gene amplification and protein overexpression are detected in up to 70% of poorly differentiated DCIS cases \[[@B7]\], and cyclin D1 is amplified and overexpressed in DCIS \[[@B8]\] in approximately 20% of the cases. Inactivating mutations of the E-cadherin gene are detected in almost all cases of lobular carcinoma *in situ*(LCIS) \[[@B9]\]. Several other genetic alterations in oncogenes (for example, C-MYC) and tumour suppressor genes (for example, p53) have been found in DCIS and are reviewed in Reis-Filho and colleagues \[[@B10]\] and Allred and colleagues \[[@B11]\].

Gene expression profiling has been shown to be a powerful tool for identifying profiles of tumour subtypes \[[@B12]-[@B15]\] and for correlating gene expression profiles with outcome in breast cancer \[[@B16]-[@B18]\]. The identification of specific gene expression patterns correlated with the different types of DCIS may help to elucidate the processes underlying the evolution of *in situ*carcinomas of the breast and also lead to a more reproducible classification of DCIS lesions.

To date, only a few studies of gene expression profiling of DCIS and a comparison with the gene expression pattern of invasive samples have been published and these are based on a small number of samples \[[@B19],[@B20]\].

In the study presented here, gene expression profiling was performed on one LCIS and 39 DCIS samples to identify differentially expressed genes between well-, intermediately, and poorly differentiated DCIS. In addition, differences in gene expression between these cases of carcinoma *in situ*and 40 invasive breast carcinomas were studied.

Materials and methods
=====================

Selection of samples
--------------------

Cases of DCIS were selected from the tissue bank of the Netherlands Cancer Institute (Amsterdam, The Netherlands). These samples were obtained within 1 hour after surgery from patients who underwent wide local excision (*n*= 16) or mastectomy (*n*= 24). All samples were reviewed by two pathologists independently to determine the histological classification of the samples according to Holland and colleagues \[[@B21]\]; samples were classified as well, intermediately, or poorly differentiated. For analysis purposes, the intermediately differentiated DCIS cases were subclassified as those cases that were in part well differentiated (well to intermediately differentiated) and those that were in part poorly differentiated (moderately to poorly differentiated) in some areas. In cases in which there was a discrepancy in classification between the two pathologists, the histological slides were reviewed together to reach an agreement.

In addition, 40 cases of primary invasive breast cancer were selected; these were all cases of invasive ductal carcinoma (IDC) measuring between 1 and 5 cm and were graded as grade 1, 2, or 3 according to the method described by Elston and Ellis \[[@B22]\]. The study was approved by the medical ethical committee of the Netherlands Cancer Institute.

RNA isolation and amplification
-------------------------------

RNA isolation and amplification were performed essentially as described by Weigelt and colleagues \[[@B23]\]. Thirty tissue sections of 30 μm of frozen material were cut. The first and the last tissue sections were 6 μm in thickness and were stained with haematoxylin and eosin to determine the percentage of tumour cells and to exclude invasive growth. Only samples with greater than or equal to50% of tumour cells were used for gene expression profiling.

Immunohistochemistry
--------------------

The procedures applied are described in the supplementary information provided online \[[@B24]\].

Microarray hybridisation
------------------------

Labeling of the amplified cRNA and microarray hybridisations were performed as previously described \[[@B25]\]. Equal amounts of amplified cRNAs of 100 invasive breast carcinomas were pooled and used as a reference. All hybridisations were performed on 18K human cDNA arrays (Central Microarray Facility, Netherlands Cancer Institute) \[[@B26]\].

Microarrays were scanned with the DNA Microarray Scanner G2565B (Agilent Technologies, Santa Clara, CA, USA). Self-self hybridisations were used to validate the quality of the hybridisations and as a negative control in the error model.

Processing of microarray data
-----------------------------

Information on data processing is provided in the supplementary information \[[@B24]\].

Unsupervised hierarchical clustering
------------------------------------

Two-dimensional unsupervised hierarchical clustering using Pearson correlation as distance function and complete linkage was performed using Genesis software (Technical University, Graz, Austria) \[[@B27],[@B28]\].

Supervised classification
-------------------------

We performed supervised classification applying methods described previously \[[@B16],[@B29],[@B30]\]. Pathological features (histological type of the DCIS samples, histological grade of the invasive samples) were used to define groups for supervised classification. Genes were rank-ordered based on their signal-to-noise statistic. Safe cutoffs were determined by comparing the signal-to-noise ratio (SNR) values with the results from 2,000 sample label permutations (Monte Carlo randomisation). For each group and a number of genes, a centroid is defined as the mean ratio per gene over all samples in that group. Correlation or Euclidean distance of each sample to those centroids determines their predicted group. Leave-out cross-validation was used to determine the optimal number of genes separating the groups. The number of left-out samples in this cross-validation procedure was dependent on the number of samples within the analysis set. SNR calculation, Monte Carlo randomisation, and cross-validation have been described previously \[[@B25]\].

Supplementary information
-------------------------

The microarray data, additional information on the methods, and the filtering results are provided as supplementary information \[[@B24]\].

Results
=======

This study was performed to identify differences in gene expression (a) between DCIS and invasive breast cancer and (b) between different histological types of DCIS.

Tumour characteristics
----------------------

Thirty-nine cases of DCIS of the breast were included in the analyses. By histological examination, they were assigned to the following groups: well differentiated (*n*= 6), intermediately differentiated (*n*= 18), and poorly differentiated (*n*= 14). For analysis purposes, the group of intermediately differentiated cases was further subdivided in well-intermediately (*n*= 10), true intermediately (*n*= 2), and intermediately-poorly (*n*= 6) differentiated type. One sample contains a mixture of well- and poorly differentiated DCIS components in the same tissue specimen. In addition, one case of LCIS was included.

To be able to compare DCIS with invasive breast cancer, 40 cases of invasive breast cancer were studied. Five tumours were histological grade 1, 11 samples were grade 2, and 24 samples were grade 3. Patient and tumour characteristics are summarised in Table [1](#T1){ref-type="table"}.

Molecular subtypes of breast cancer
-----------------------------------

Several subtypes of breast cancer have been identified by gene expression profiling and have been correlated with clinical outcome \[[@B13],[@B14]\]. This classification has been translated to classical immunohistochemistry (IHC): basal-type tumours are characterised by negative staining for oestrogen receptor (ER), progesterone receptor, and HER2 and are often positive for keratin 5/6; ERB-B2 tumours are HER2-positive, and luminal A and B tumours are ER-positive and HER2-negative. In our set of 40 *in situ*tumours, only two tumours are positive for CK5/6 by IHC. Both of them are poorly differentiated and negative for HER2 and ER by IHC. From the intrinsic gene set identified by Perou and colleagues \[[@B12]\], we could match 403 identifiers to our array platform. This set of genes was used to perform unsupervised hierarchical clustering of the 40 *in situ*samples. We clearly see a discrimination between tumours highly expressing genes of the luminal/ESR1 cluster and tumours negative for these genes, whereas the discrimination for the HER2-overexpressing groups was much less clear (Figure [1](#F1){ref-type="fig"} in the supplementary information \[[@B24]\]). We could not identify a large basal-type group, which is in agreement with the data obtained using IHC.

Unsupervised hierarchical clustering
------------------------------------

### Unsupervised hierarchical clustering of *in situ*and invasive samples

First, the whole group of DCIS and invasive samples was clustered (Figure [1a](#F1){ref-type="fig"}). As can be seen, the invasive samples cluster in three different groups (indicated as I, II, and III in Figure [1a](#F1){ref-type="fig"}). Ten out of 14 poorly differentiated DCIS samples cluster together in a fourth group, and a fifth group consists of 13 out of 18 cases of intermediately differentiated DCIS and four out of six of the well-differentiated *in situ*samples. The clustering seems not to be driven mainly by the ER status or the HER2 status of the samples. These results suggest that poorly differentiated DCIS samples show an overall gene expression profile other than that of the intermediately and well-differentiated DCIS samples.

### Unsupervised hierarchical clustering of DCIS

We also performed unsupervised hierarchical cluster analysis to the series of DCIS cases only, resulting in two large groups. One group contains 10 poorly differentiated samples and only one well-differentiated sample, whereas 83% of the well-differentiated samples group in the other, second cluster. Most of the samples in this second group are ER-positive by IHC. In total, our sample set contains 18 cases with an intermediately differentiated component. Of these samples, 12 cluster in the arm of the well-differentiated samples. In accordance with the clustering results presented in Figure [1](#F1){ref-type="fig"}, these results also indicate that the overall gene expression profiles of *in situ*samples with an intermediately differentiated component are more similar to those of well-differentiated DCIS than to those of poorly differentiated DCIS. It is clear from these results that there are large differences in gene expression pattern between well- and poorly differentiated DCIS.

Supervised classification
-------------------------

We performed supervised classification on different data sets to identify the genes differentially expressed between the groups of interest. These groups are (a) 40 *in situ*versus 40 invasive breast carcinomas, (b) 14 poorly differentiated DCIS cases versus 38 invasive grade 3 tumours, and (c) six cases of well-versus 14 cases of poorly differentiated DCIS.

### Supervised classification of *in situ*versus invasive carcinomas

We investigated the differences in gene expression between *in situ*and invasive breast carcinoma samples. We therefore used the whole data set and assigned all 40 *in situ* samples to one group and all 40 invasive samples to a second group (analysis set 1). To obtain a profile taking into account the expression sets of both tumour types, significantly regulated genes were identified independently for both groups. The 1,706 overlapping genes were used for analysis. Monte Carlo randomisation revealed approximately 300 genes differentially expressed between *in situ*and invasive samples.

After cross-validation, classifier consisting of 35 genes resulted in a stable prediction of the differences between DCIS and invasive breast carcinomas, with an average performance of 91%. The gene list is provided in Table [2](#T2){ref-type="table"}.

### Supervised classification for poorly differentiated DCIS versus grade 3 invasive carcinoma

Because it is very likely that grade 3 invasive breast cancer arises from poorly differentiated DCIS \[[@B5],[@B6]\], we applied the supervised classification procedure to the subset of poorly differentiated DCIS (*n*= 14) and grade 3 invasive tumours (*n*= 24) (analysis set 2). Again, the filtering procedure was applied to both groups independently. The overlapping fraction of this gene list contains 1,119 genes that were used to perform the analyses. Monte Carlo randomisation showed that 80 genes are differentially expressed between poorly differentiated DCIS and grade 3 invasive breast carcinoma samples. After cross-validation in 14 steps, the best performance of 93% is reached, when at least 50 genes are used to build the classifier. This performance remains stable with increasing numbers of genes. This means that 50 to 80 genes are able to discriminate between poorly differentiated DCIS and invasive grade 3 breast tumours (Figure [2a](#F2){ref-type="fig"}). These 80 genes are shown in Table [3](#T3){ref-type="table"}. Between the 35-gene classifier of all DCIS and invasive samples and the subgroup classifier of 80 genes, 21 genes were present in both classifiers.

### Supervised classification of well-versus poorly differentiated DCIS

We intended to find the most prominent differences between the well- and poorly differentiated DCIS samples. Sixfold cross-validation of six well- and 14 poorly differentiated *in situ*samples (analysis set 3) resulted in a set of 43 genes separating these groups with a performance of 90% (Figure [3a](#F3){ref-type="fig"}, Table [4](#T4){ref-type="table"}).

Because histological classification of intermediately differentiated DCIS versus well- or moderately differentiated DCIS is most challenging, we investigated whether gene expression profiling could be used to identify markers that could help in making this classification. We therefore included the cases classified as intermediately differentiated DCIS. Subsequently, we divided the sample set into one group of well/well-intermediately differentiated samples (*n*= 16) and a second group containing poorly/intermediately-poorly differentiated samples (*n*= 20). Supervised classification of these data revealed a set of 78 genes separating these two groups with an average performance of 89% (Table [5](#T5){ref-type="table"}).

We observed a separation of this data set in three distinct groups (Figure [3](#F3){ref-type="fig"}). One group contains one intermediately-poorly differentiated sample (17%) and 12 out of 14 poorly differentiated samples, and a second group all six well-differentiated samples and seven out of 10 well-intermediately differentiated samples. The third group shows no correlation with both profiles and consists of five out of six intermediately-poorly and three out of 10 well-intermediately differentiated samples. This implies that this third group typifies mainly the intermediately-poorly differentiated samples. Well-intermediately differentiated samples are apparently very similar to well-differentiated DCIS in their gene expression. These results are in accordance with the results of unsupervised hierarchical clustering of all *in situ*samples (Figure [4a](#F4){ref-type="fig"}).

Twenty-one genes are overlapping between the 43 genes of analysis set 3 and the 78 genes of analysis set 4. It is known that many poorly differentiated *in situ*breast carcinomas do not express the ER. In our data set, nine of all 14 poorly differentiated DCIS samples (64%) are negative for ER expression by IHC. There was a slight chance that our classifier would detect mainly the differences of ER-associated genes. We identified only one gene (*LIV-1*), beside the ER itself, directly ER-regulated in the classifier of 43 genes. Additionally, we compared the 43 genes with 2,460 ER-associated genes identified by van \'t Veer and colleagues \[[@B16]\]. Thirteen genes, including the ER itself, have been found in both gene lists. So, most of the genes in this 43-gene classifier have not been correlated to ER expression so far, indicating that the differences between well- and poorly differentiated DCIS samples are not originating from the ER status of the samples.

Remarkably, completely different gene lists are found describing the differences in gene expression between different *in situ*samples, on one hand, and DCIS and invasive samples on the other hand. These findings may indicate that gene regulation involved in progression from *in situ*to invasive breast cancer affects molecular mechanisms other than the mechanisms responsible for the development of the different types of DCIS.

Discussion
==========

Although studies to identify gene expression signatures in DCIS are limited by difficulties in obtaining frozen material from DCIS, we were able to collect a relatively large series of DCIS cases for this purpose. It should be kept in mind that we did not have a sufficient number of cases to validate the gene expression signatures that we identified.

We were able to show that well- (*n*= 6) and poorly (*n*= 14) differentiated DCIS show different gene expression profiles and can be distinguished by a classifier of 43 genes. Most of the genes differentially expressed between well- and poorly differentiated DCIS are involved in metabolism (for example, *BTD*, *ETFA*, *GMFG*, and *PLAT*) and cell communication (for example, *ESR1*, *ACK1*, *CELSR2*, and *CCL19*).

One of the top genes in the 43-gene classifier is *BCL2*. The mRNA expression of this anti-apoptotic protein is upregulated in the well-differentiated samples. In addition to its anti-apoptotic function, BCL2 has a suggested role in neuro-endocrine differentiation in colon carcinomas \[[@B31]\] and its downregulation is associated with poor prognosis in breast cancer \[[@B32]\].

Twenty-eight of the 43 genes are upregulated and 15 genes are downregulated in the well-differentiated samples (Figure [3a](#F3){ref-type="fig"}). Whereas a number of the 28 upregulated genes are involved in DNA binding, no genes fulfilling this function are on the list of the 15 downregulated genes. Conversely, genes involved in phosphate metabolism (for example, *GMFG*, *ACK1*, and *ATP5B*) can be found within the 15 downregulated, but not in the 28 upregulated, genes.

It is known that HER2 is overexpressed in poorly differentiated DCIS in approximately 42% of the cases \[[@B7]\], and it has been suggested that HER2 overexpression is an early step in the evolution of a distinct type of breast carcinoma. In our data set of all *in situ*samples, we found a positive log2-ratio for HER mRNA expression in six of 14 poorly differentiated DCIS cases (43%) and in one case of intermediately-poorly differentiated DCIS. In all the other *in situ*samples, the log2-ratios of HER2 are negative. These results are in agreement with the hypothesis that HER2 overexpression is an early event in the development of poorly differentiated *in situ*breast carcinomas.

Supervised classification of well-, well-intermediately, intermediately-poorly, and poorly differentiated DCIS samples (analysis set 4) showed a separation of these samples in three groups: a \'good\' group, a \'poor\' group, and an \'intermediate\' group containing mostly samples that were identified as intermediately-poorly differentiated samples by pathologists. This group also contains some samples pathologically classified as well-intermediately differentiated, whereas most of these samples fall in the \'good\' group. These results indicate that well- and well-intermediately differentiated DCIS are more similar to each other than poorly and intermediately-poorly differentiated DCIS are. Following this idea, well- and well-intermediately differentiated samples may be considered to be one group, whereas poorly and intermediately-poorly differentiated samples seem to be two distinct groups of DCIS. If these results can be validated in additional studies, this classification could help to decrease controversial classification of DCIS due to interobserver variability and to recognise well-differentiated DCIS with more accuracy.

Within the gene lists describing the differences between well- and poorly differentiated DCIS, a number of genes refer to proteins for which antibodies are available. There is no single gene discriminating between the different types of DCIS, but it has to be investigated whether a combination of protein stainings in a patient\'s tissue can assist in better classification of DCIS. From the study presented here, potential candidates for such an approach are *Bcl-2*, *Ack1*, *CCL19*, and *CELSR2*, among others.

Thirty-five genes are able to describe the global differences in gene expression between *in situ*and invasive breast tumour samples. This classifier contains many genes involved in signal transduction (for example, *APC2*, *DAPK3*, *ADM*, *ARF1*, and *IQGAP1*) and cell growth and maintenance (*TGFB2*, *PTMS*, *PSAP*, *TUBB2*, and *MAP7*).

The most likely model describing the progression from *in situ*to invasive breast cancer lesions is the existence of distinct pathways for the evolution of well- and poorly differentiated DCIS. Following this idea, well-differentiated *in situ*lesions develop into grade 1 IDC, whereas poorly differentiated samples develop into grade 3 IDC \[[@B5],[@B6]\]. We therefore performed supervised classification on the set of poorly differentiated DCIS (*n*= 14) and grade 3 invasive breast cancer (*n*= 24).

Approximately 80 genes discriminate poorly differentiated *in situ*from grade 3 invasive breast carcinomas. Thirteen of these 80 genes are upregulated and 67 genes are downregulated in poorly differentiated DCIS samples. The genes in this classifier are involved mostly in cell growth and protein metabolism. Many of them have a function in protein binding (for example, *LCP1*, *TRAP1*, *ID4*, *TOB1*, and *CDH*) and nucleic acid binding (for example, *FBL*, *PIAS4*, *ELF3*, *EIF4G1*, *NBS1*, and *WHSC1L1*).

A limited number of previous studies have addressed gene expression profiles in DCIS, and most of these studies have analysed a small number of samples. One study by Seth and colleagues \[[@B20]\] compared one case of low- to intermediate-grade DCIS with one case of high-grade DCIS with an invasive component and identified genes upregulated or downregulated in the low- to intermediate-grade DCIS case. Adeyinka and colleagues \[[@B19]\] studied six cases of DCIS with necrosis and four samples of DCIS without necrosis and identified a signature of 69 transcripts differentially expressed between these two groups. Ma and colleagues \[[@B33]\] used laser capture microdissection from paraffin-embedded material followed by gene expression profiling to identify molecular signatures in premalignant, preinvasive, and invasive stages of breast cancer. The results of their study suggested that tumour grade, rather than tumour stage, is associated with distinct gene expression patterns and that changes in gene expression required for invasive growth are already present in the DCIS stage \[[@B33]\]. In the study presented here, we compared the gene expression profiles of poorly differentiated DCIS lesions with those in grade 3 invasive breast tumours. In contrast to Ma and colleagues, we did not compare paired samples from the same patient but compared two groups of tumours. The 80-gene signature we identified is different from the signatures describing the differences between different grades of DCIS lesions. Schuetz and colleagues \[[@B34]\] identified gene expression signatures of *in situ*and invasive breast cancer by using 18 paired samples and combining laser capture microdissection and gene expression profiling on oligonucleotide microarrays. They showed that 546 probes were differentially expressed between DCIS and IDC. From the 18 genes they validated by real-time polymerase chain reaction, four (*MMP11*, *PLAU*, *BGN*, and *FAP*) are also present in our filtered data sets of significantly regulated probe sets comparing DCIS and invasive samples. They all show the same expression pattern as described by Schuetz and colleagues and are expressed at higher levels in the groups of invasive tumours. One of these genes (*MMP11*) is also part of the 35-gene and 80-gene classifiers. *MMP11*and *PLAU*have already been correlated to invasion and poor prognosis \[[@B35],[@B36]\]. *FAP*(seprase) is a membrane-bound protease that has been suggested to reduce the dependence of breast cancer cells on exogenous growth factors *in vitro*and thereby to facilitate tumour growth and metastasis \[[@B37]\]. Allinen and colleagues \[[@B38]\] identified comprehensive gene expression profiles of the different cell types in normal breast, DCIS, and invasive breast cancer tissue. These data show that dramatic gene expression changes occur between normal breast tissue and breast carcinomas and that these changes are already present at the DCIS stage. These results also suggest a role of the chemokines CXCL12 and CXCL14 in breast tumourigenesis. Neither chemokine is present on our array platform, but CXCR4, which is the receptor for CXCL12, is. *CXCR4*does not appear in the set of significantly regulated genes, indicating that it does not play a crucial role in our series of tumours, which reflects the data of a mixed population of cells enriched for tumour cells, whereas Allinen and colleagues performed gene expression profiling on microdissected cell populations.

A recent study by Nagaraja and colleagues \[[@B39]\] describes gene expression patterns corresponding to normal breast, noninvasive breast cancer, and invasive breast cancer by using several cell lines. They identified genes involved in cell-cell and cell-matrix interactions which were altered in their expression. A set of nine genes was sufficient to distinguish between invasive and non-invasive cell lines \[[@B39]\]. From this set of nine transcripts, six could be matched to our array platform. For three of them (cadherin 11, annexin A1, and vimentin), we observe the same expression pattern as published by Nagaraja and colleagues for the transition from *in situ*to invasive carcinoma. The other three transcripts (S100A8, claudin 3, and cadherin 1) are upregulated in the invasive cancer cell line in the data set of Nagaraja and colleagues, whereas we see a downregulation in the invasive grade 3 tumours compared with the group of poorly differentiated samples. This may be due to the fact that Nagaraja and colleagues generated *in vitro*data, which we compared with our human breast cancer data set.

Porter and colleagues \[[@B40]\] identified a subset of genes that are significantly regulated in DCIS or invasive carcinomas. They identified 26 genes that were differentially expressed between normal and DCIS samples or intermediate- and high-grade DCIS, respectively. From these, only *XBP1*is present in one of our classifiers (78 genes). Porter and colleagues describe this transcript as tumour-specific, meaning upregulated in *in situ*and invasive tumours compared with their normal samples. We find that *XBP1*is significantly more highly expressed in well- and well-intermediately differentiated DCIS samples than in poorly/intermediately-poorly differentiated ones.

Wulfkuhle and colleagues \[[@B41]\] performed proteomic analyses of six matched normal and DCIS samples of the human breast. They identified proteins that are more highly expressed in individual DCIS samples and that are involved in cytoskeletal regulation or vesicular trafficking or have chaperone activity. From the 15 proteins from which the expression has been validated by IHC, 12 are present as probes on our array platform. Three of those (profilin, stathmin, and prohibitin) are differentially regulated between DCIS and invasive samples, and all three show a higher expression in the invasive samples than in the DCIS samples. This is in line with the paper of Wulfkuhle and colleagues, which describes a higher expression of these proteins in the DCIS samples than in normal tissue. This indicates that changes in gene and protein expression observed in invasive tumours are already present in the transition from normal tissue to DCIS lesions.

Conclusion
==========

We demonstrate here that gene expression profiling can distinguish between *in situ*breast cancer samples of well-versus poorly differentiated type. There appear to be a group of poorly differentiated samples, a group of well- and well-intermediately differentiated samples, and a third group containing mainly intermediately-poorly differentiated *in situ*cases. The quantitative differences in gene expression between these groups are mainly between twofold and fourfold. These differences are difficult to detect by classical IHC, because this technique is not very accurate in the quantification of small differences in protein expression. So far, there are no single markers that distinguish between the different types of DCIS, but the possibility of identifying a manageable panel of markers to distinguish the different types of DCIS lesions has to be further investigated.
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![Unsupervised hierarchical clustering of *in situ*and invasive samples. **(a)**Dendrogram of all *in situ*(*n*= 40) and all invasive (*n*= 40) samples. **(b)**Scaled-down representation of the entire cluster shown in **(a)**(1,706 genes). **(c)**Dendogram of poorly differentiated ductal carcinoma *in situ*(*n*= 14) and grade 3 invasive (*n*= 24) samples. **(d)**Entire cluster of **(c)**(1,119 genes). Yellow indicates *in situ*samples, and blue indicates invasive samples. i, intermediately differentiated; IHC, immunohistochemistry; i/p, intermediately/poorly differentiated; LCIS, lobular carcinoma *in situ*; p, poorly differentiated; w, well differentiated; w/i, well/intermediately differentiated.](bcr1613-1){#F1}

![Euclidean distance and heatmaps of the *in situ*and invasive samples using the classifiers obtained after cross-validation. **(a)**All ductal carcinoma *in situ*(DCIS) (*n*= 40) and all invasive (*n*= 40) samples. The classifiers consist of 80 genes. **(b)**Poorly differentiated DCIS (*n*= 14) versus invasive grade 3 samples (*n*= 24) using a classifier of 35 genes. p, poorly differentiated.](bcr1613-2){#F2}

![Correlation plots and heatmaps of the *in situ*samples using the classifiers obtained after cross-validation. **(a)**Well- (*n*= 6) versus poorly (*n*= 14) differentiated ductal carcinoma *in situ*(DCIS). The classifiers consist of 43 genes. **(b)**Well-/well-intermediately (*n*= 16) versus intermediately-poorly/poorly (*n*= 20) differentiated DCIS using a classifier of 78 genes. i-p, intermediately-poorly differentiated; p, poorly differentiated; w, well differentiated; w-i, well-intermediately differentiated.](bcr1613-3){#F3}

![Unsupervised hierarchical clustering of the *in situ*samples. **(a)**Dendrogram of all 40 *in situ*samples. **(b)**Scaled-down representation of the entire cluster of **(a)**(5,788 genes). **(c)**Dendrogram of only the well- (*n*= 6) and poorly (*n*= 14) differentiated ductal carcinoma *in situ*(DCIS) cases. **(d)**Entire cluster of **(c)**(4,493 genes). Yellow indicates well-differentiated DCIS, brown indicates poorly differentiated DCIS, black indicates DCIS samples with an intermediately differentiated component, and gray indicates special cases. i, intermediately differentiated; IHC, immunohistochemistry; i-p, intermediately-poorly differentiated; LCIS, lobular carcinoma *in situ*; p, poorly differentiated; w, well differentiated; w-i, well-intermediately differentiated.](bcr1613-4){#F4}

###### 

Patient characteristics

  *In situ*samples                        Invasive samples                               
  --------------------------------------- --------------------- ------------------------ ---------------------
  Differentiation                         Number (percentage)   Histological grade       Number (percentage)
                                                                                         
  Well                                    6 (15%)               1                        5 (12.5%)
  Intermediately                          18 (45%)              2                        11 (27.5%)
  Poorly                                  14 (35%)              3                        24 (60%)
  Good/poor component                     1 (2.5%)                                       
  LCIS                                    1 (2.5%)                                       
  IHC                                                           IHC                      
  ER-positive                             28 (70%)^a^           ER-positive              22 (55%)^c^
  PR-positive                             24 (60%)^a^           PR-positive              19 (47.5%)^d^
  Her2/neu-positive (3+)                  12 (30%)^b^           Her2/neu-positive (3+)   4 (10%)^d^
  p53-positive                            11 (27.5%)^b^         p53-positive             9 (22.5%)^d^
  Tumour detection                                                                       
  Palpation                               17 (42.5%)                                     
  Microcalcifications                     18 (45%)                                       
  Others                                  5 (12.5%)                                      
  Tumour diameter (mm)                                                                   
  Range                                   10 to 80                                       
  Median                                  45                                             
  Average                                 42.8                                           
  Treatment                                                                              
  Mastectomy                              24 (60%)                                       
  Breast conserving treatment             6 (15%)                                        
  Local excision followed by mastectomy   10 (25%)                                       

^a^5% not assessable, ^b^2.5% not assessable, ^c^27.5% not assessable, ^d^30% not assessable. ER, oestrogen receptor; IHC, immunohistochemistry; LCIS, lobular carcinoma *in situ*; PR, progesterone receptor.

###### 

List of 35 genes able to discriminate between all DCIS and all invasive samples

  Rank   NKI ID   Symbol       Annotation                                                                                                 Accession no.
  ------ -------- ------------ ---------------------------------------------------------------------------------------------------------- ------------------
  1      116810   *ADM*        Adrenomedullin                                                                                             AA446120
  2      123346                EST                                                                                                        H17315
  3      117289   *MMP11*      Matrix metalloproteinase 11 (stromelysin 3)                                                                AA045500
  4      121066   *DAPK3*      Death-associated protein kinase 3                                                                          AA973730
  5      123776   *PIAS4*      Protein inhibitor of activated STAT protein                                                                H30547
  6      101837   *DHX34*      KIAA0134 gene product                                                                                      AA477623
  7      102847   *YIF1*       Putative transmembrane protein; homolog of yeast Golgi membrane protein Yif1p (Yip1p-interacting factor)   H79351
  8      117345   *ACTN1*      Actinin, alpha 1                                                                                           AA669042
  9      127755   *TGFB2*      Transforming growth factor, beta 2                                                                         W47556
  10     108960   *GABRD*      Gamma-aminobutyric acid (GABA) A receptor, delta                                                           H41122
  11     108348   *MFAP2*      Microfibrillar-associated protein 2                                                                        N67487
  12     129658   *MGC13045*   DnaJ (Hsp40) homolog, subfamily C, member 4                                                                AA996059
  13     105479   *BAT3*       HLA-B-associated transcript-3                                                                              AA434416
  14     120649   *KCTD5*      Hypothetical protein                                                                                       AA521027
  15     110728   *FBXL15*     F-box and leucine-rich repeat protein 15                                                                   T61547
  16     120934   *EIF4G1*     Eukaryotic translation initiation factor 4 gamma, 1                                                        R37276
  17     118584   *C9orf115*   ESTs, weakly similar to B36298 proline-rich protein PRB3S \[*Homo sapiens*\]                               AA479713
  18     105533   *ARF1*       ADP-ribosylation factor 1                                                                                  W45572
  19     131909   *TUBB2*      Tubulin, beta polypeptide                                                                                  AI672565
  20     131540   *PRPF31*     DKFZP566J153 protein                                                                                       AI253017
  21     110281   *HSPA1L*     Heat shock 70-kD protein-like 1                                                                            H17513
  22     107215   *KCTD5*      Hypothetical protein                                                                                       AA429470
  23     121937   *FLJ10374*   Hypothetical protein FLJ10374                                                                              AA676962
  24     100368   *GNB2*       Guanine nucleotide binding protein (G protein), beta polypeptide 2                                         N68166
  25     105453   *PSAP*       Prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)                              N72215
  26     115391   *LMCD1*      LIM and cysteine-rich domains 1                                                                            AA452125
  27     128198   *MMP11*      Matrix metalloproteinase 11 (stromelysin 3)                                                                AA954935
  28     123688   *COL1A1*     Collagen, type I, alpha 1                                                                                  R48844
  29     127890   *PTMS*       Parathymosin                                                                                               AA458981
  30     102044   *DRAP1*      DR1-associated protein 1 (negative cofactor 2 alpha)                                                       AA406285
  31     101067   *MAP7*       Microtubule-associated protein 7                                                                           R77252 \| R77251
  32     129438   *IQGAP1*     IQ motif containing GTPase activating protein 1                                                            AA478633
  33     125700   *APC2*       Adenomatous polyposis coli like                                                                            AA976241
  34     127881   *NFIC*       Nuclear factor I/C (CCAAT-binding transcription factor)                                                    T59427
  35     109065   *SYT5*       Synaptotagmin V                                                                                            H39018

DCIS, ductal carcinoma *in situ*; EST, expressed sequence tag; NKI ID, Netherlands Cancer Institute (Amsterdam, The Netherlands) identification number.

###### 

List of 80 genes able to discriminate between poorly differentiated DCIS and invasive grade 3 breast tumours

  Rank   NKI ID   Symbol        Annotation                                                                                                 Accession no.
  ------ -------- ------------- ---------------------------------------------------------------------------------------------------------- ----------------------
  1      123776   *PIAS4*       Protein inhibitor of activated STAT protein                                                                H30547
  2      129658   *MGC13045*    DnaJ (Hsp40) homolog, subfamily C, member 4                                                                AA996059
  3      121937   *FLJ10374*    Hypothetical protein FLJ10374                                                                              AA676962
  4      102847   *YIF1*        Putative transmembrane protein; homolog of yeast Golgi membrane protein Yif1p (Yip1p-interacting factor)   H79351
  5      127755   *TGFB2*       Transforming growth factor, beta 2                                                                         W47556
  6      117289   *MMP11*       Matrix metalloproteinase 11 (stromelysin 3)                                                                AA045500
  7      104973   *SYNPO2*      Synaptopodin 2                                                                                             R31679
  8      121066   *DAPK3*       Death-associated protein kinase 3                                                                          AA973730
  9      128493   *GMFG*        Glia maturation factor, gamma                                                                              AI311932
  10     105533   *ARF1*        ADP-ribosylation factor 1                                                                                  W45572
  11     132031                 NY-REN-24 antigen                                                                                          AA918005
  12     127881   *NFIC*        Nuclear factor I/C (CCAAT-binding transcription factor)                                                    T59427
  13     120649   *KCTD5*       Potassium channel tetramerisation domain containing 5                                                      AA521027
  14     120934   *EIF4G1*      Eukaryotic translation initiation factor 4 gamma, 1                                                        R37276
  15     105453   *PSAP*        Prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)                              N72215
  16     112695   *SYNPO2*      *H. sapiens*cDNA FLJ20767 fis, clone COL06986                                                              AA043349
  17     101577   *BMI1*        Murine leukaemia viral (bmi-1) oncogene homolog                                                            AA478036
  18     105479   *BAT3*        HLA-B-associated transcript-3                                                                              AA434416
  19     123071   *C9orf82*     Hypothetical protein FLJ13657                                                                              AA135972
  20     101638   *ID4*         Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein                                     AA464856
  21     115306   *LRP16*       LRP16 protein                                                                                              AA456318
  22     118143   *STX1B2*      ESTs, moderately similar to ST1B_HUMAN SYNTAXIN 1B \[*H. sapiens*\]                                        H41572
  23     128106   *DUSP6*       Dual specificity phosphatase 6                                                                             AA455254
  24     115676   *RPS15A*      Ribosomal protein S15a                                                                                     AA411682
  25     108595   *CCL19*       Small inducible cytokine subfamily A (Cys-Cys), member 19                                                  AA680186
  26     126589   *C6orf166*    Hypothetical protein FLJ10342                                                                              AA984953
  27     131540   *PRPF31*      DKFZP566J153 protein                                                                                       AI253017
  28     109065   *SYT5*                                                                                                                   H39018
  29     128198   *MMP11*       Matrix metalloproteinase 11 (stromelysin 3)                                                                AA954935
  30     109364   *MYST2*       Histone acetyltransferase                                                                                  H11938
  31     106989   *TNFSF13*     Tumour necrosis factor (ligand) superfamily, member 13                                                     AA443577
  32     109798                                                                                                                            T82459
  33     131890   *CDH1*        Cadherin 1, type 1, E-cadherin (epithelial)                                                                AI671174
  34     111513   *COG3*        *H. sapiens*clone 25226 mRNA sequence                                                                      AA461166
  35     108645   *HMGCS2*      3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial)                                           AA496149
  36     101651   *TRAP1*       Heat shock protein 75                                                                                      AA497020
  37     105304   *LRP16*       LRP16 protein                                                                                              W52182 \| AA284285
  38     105363   *ARL7*        ADP-ribosylation factor-like 7                                                                             AA485683
  39     127890   *PTMS*        Parathymosin                                                                                               AA458981
  40     118682   *NBS1*        Nijmegen breakage syndrome 1 (nibrin)                                                                      H98655
  41     108997   *PTTG1IP*     Pituitary tumour-transforming 1 interacting protein                                                        AA156461
  42     110281   *HSPA1L*      Heat shock 70-kD protein-like 1                                                                            H17513
  43     125700   *APC2*        Adenomatous polyposis coli like                                                                            AA976241
  44     117139   *ALDOB*       Aldolase B, fructose-bisphosphate                                                                          H72098
  45     107595   *SOX17*       SRY-box 17                                                                                                 AA427400 \| AI732705
  46     107375   *NUCKS*       Similar to rat nuclear ubiquitous casein kinase 2                                                          AA137266
  47     109238   *BSG*         Basigin (OK blood group)                                                                                   AA436440
  48     122821   *NSE2*        ESTs                                                                                                       H30453
  49     123689   *LOC339123*   STIP1 homology and U-Box containing protein 1                                                              R54844
  50     115953   *LOC146542*   Human Chromosome 16 BAC clone CIT987SK-A-635H12                                                            AA455010
  51     108960   *GABRD*                                                                                                                  H41122
  52     128222   *GLUL*        Glutamate-ammonia ligase (glutamine synthase)                                                              AI000103
  53     100222   *NFIX*        Nuclear factor I/X (CCAAT-binding transcription factor)                                                    AA406269
  54     105470   *ISYNA1*      Myo-inositol 1-phosphate synthase A1                                                                       AA454554
  55     117998   *RBM9*        RNA binding motif protein 9                                                                                H03903
  56     105404   *GDF15*       Prostate differentiation factor                                                                            N26311
  57     127811   *TOB1*        Transducer of ERBB2, 1                                                                                     W96163
  58     105524   *RPS6KA4*     Ribosomal protein S6 kinase, 90-kD, polypeptide 4                                                          AA443601
  59     109232   *BCKDHA*      Branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease)                   AA477298
  60     115741   *APPL*        Adaptor protein containing pH domain, PTB domain and leucine zipper motif                                  AA436158
  61     100898   *ELF3*        E74-like factor 3 (ets domain transcription factor, epithelial-specific)                                   AA434373
  62     101067   *MAP7*        Microtubule-associated protein 7                                                                           R77252 \| R77251
  63     109306   *AQP1*        Aquaporin 1 (channel-forming integral protein, 28 kD)                                                      H24316
  64     102326   *CYC1*        Cytochrome c-1                                                                                             AA447774
  65     108988   *MALAT1*      Histone deacetylase 3                                                                                      H88540
  66     102253   *ACTG2*       Actin, gamma 2, smooth muscle, enteric                                                                     T60048
  67     116834   *GPC1*        Glypican 1                                                                                                 AA455896
  68     105497   *HNRPK*       Heterogeneous nuclear ribonucleoprotein K                                                                  W85697
  69     108372   *LCP1*        Lymphocyte cytosolic protein 1 (L-plastin)                                                                 W73144
  70     128634   *PRCP*        Prolylcarboxypeptidase (angiotensinase C)                                                                  AI360366
  71     106297   *PHF17*       Hypothetical protein FLJ22479                                                                              AA136664
  72     101616   *KRT19*       Keratin 19                                                                                                 AA464250
  73     128532   *LTB*         Lymphotoxin beta (TNF superfamily, member 3)                                                               AI351740
  74     102385   *F13A1*       Coagulation factor XIII, A1 polypeptide                                                                    AA449742
  75     102673   *WHSC1L1*     Wolf-Hirschhorn syndrome candidate 1-like 1                                                                T97900
  76     109638   *CXXC1*       CpG binding protein                                                                                        T60082
  77     109116   *FBL*         Fibrillarin                                                                                                AA663986
  78     109425   *TUBB*        Tubulin, beta polypeptide                                                                                  AA427899
  79     117500                 EST                                                                                                        AA621138
  80     100656   *UBE2C*       Ubiquitin carrier protein E2-C                                                                             AA430504

DCIS, ductal carcinoma *in situ*; EST, expressed sequence tag; NKI ID, Netherlands Cancer Institute (Amsterdam, The Netherlands) identification number.

###### 

List of 43 genes able to discriminate between well- and poorly differentiated DCIS

  Rank   NKI ID   Symbol       Annotation                                                                                           Accession no.
  ------ -------- ------------ ---------------------------------------------------------------------------------------------------- ---------------
  1      108691   *ACK1*       Activated p21cdc42Hs kinase                                                                          AA427891
  2      109246   *BCL2*       B-cell CLL/lymphoma 2                                                                                W63749
  3      109268   *ALDH3A2*    Aldehyde dehydrogenase 3 family, member A2                                                           AA633569
  4      109236   *BTD*        Biotinidase                                                                                          R17765
  5      108595   *CCL19*      Small inducible cytokine subfamily A (Cys-Cys), member 19                                            AA680186
  6      100524   *CELSR2*     Cadherin, EGF LAG seven-pass G-type receptor 2, flamingo (Drosophila) homolog                        H39187
  7      126868   *TMC4*       DKFZP586J0619 protein                                                                                AA991211
  8      100708   *SLC39A6*    LIV-1 protein, oestrogen regulated                                                                   H29315
  9      109170   *C4A*        Complement component 4A                                                                              AA664406
  10     109127   *ESR1*       Oestrogen receptor 1                                                                                 AA291749
  11     128702                EST                                                                                                  AI313031
  12     121012   *HSHIN1*     Hin-1                                                                                                AA902831
  13     128095   *PCSK6*      Paired basic amino acid cleaving system 4                                                            W85807
  14     128052   *ARHGEF7*    PAK-interacting exchange factor beta                                                                 AA452871
  15     128493   *GMFG*       Glia maturation factor, gamma                                                                        AI311932
  16     123382   *HIG1*       Likely ortholog of mouse hypoxia induced gene 1                                                      T74105
  17     129689   *C1orf21*    Chromosome 1 open reading frame 21                                                                   AA406569
  18     102289   *ETFA*       Electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II)                             T57919
  19     126124   *FLJ20152*   Hypothetical protein                                                                                 AA918685
  20     127815   *PLAT*       Plasminogen activator, tissue                                                                        R38933
  21     101559   *NPY1R*      Neuropeptide Y receptor Y1                                                                           R43817
  22     100260   *MAL*        Mal, T-cell differentiation protein                                                                  AA227885
  23     127969   *CRYAA*      Crystallin, alpha A                                                                                  H84722
  24     128244   *SERPINA3*   Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3   AA704242
  25     108649                Human clone 23948 mRNA sequence                                                                      H15114
  26     106399   *GRTP1*      Hypothetical protein FLJ22474                                                                        N52651
  27     123478   *FLJ14712*   Hypothetical protein FLJ14712                                                                        N79050
  28     117207   *EMP3*       Epithelial membrane protein 3                                                                        W73810
  29     111787   *ZNF451*     *H. sapiens*cDNA FLJ13010 fis, clone NT2RP3000542                                                    AA486412
  30     109502   *KITLG*      *H. sapiens*cDNA: FLJ21592 fis, clone COL07036                                                       H11088
  31     109315   *UCP2*       Uncoupling protein 2 (mitochondrial, proton carrier)                                                 H61243
  32     118532   *NUPL1*      PRO2463 protein                                                                                      AA772502
  33     100263   *MYB*        V-myb avian myeloblastosis viral oncogene homolog                                                    N49284
  34     128249   *CD3E*       CD3E antigen, epsilon polypeptide (TiT3 complex)                                                     AA933862
  35     131226   *IL7R*       Interleukin 7 receptor                                                                               T65739
  36     100104   *SELL*       Selectin L (lymphocyte adhesion molecule 1)                                                          H00662
  37     108671   *BCAT2*      Branched chain aminotransferase 2, mitochondrial                                                     AA436410
  38     116984   *ATP5B*      ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide                            AA708298
  39     108376   *LAMA3*      Laminin, alpha 3 (nicein \[150 kD\], kalinin \[165 kD\], BM600 \[150 kD\], epilegrin)                AA001432
  40     104944   *SLC7A2*     Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2                       R26163
  41     100840   *THOC1*      Nuclear matrix protein p84                                                                           AA129297
  42     100650   *SHFM1*      Deleted in split-hand/split-foot 1 region                                                            H85464
  43     101429   *SIAT1*      Sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase)                                    AA598652

DCIS, ductal carcinoma *in situ*; EST, expressed sequence tag; NKI ID, Netherlands Cancer Institute (Amsterdam, The Netherlands) identification number.

###### 

List of 78 genes able to discriminate between well/well-intermediately and intermediately-poorly/poorly differentiated DCIS

  Rank   NKI ID   Symbol        Annotation                                                                                                                   Accession no.
  ------ -------- ------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------
  1      111275                 EST                                                                                                                          H20757
  2      109268   *ALDH3A2*     Aldehyde dehydrogenase 3 family, member A2                                                                                   AA633569
  3      109236   *BTD*         Biotinidase                                                                                                                  R17765
  4      110384   *KPNA2*       Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)                                                                         AA676460
  5      131448   *PLEKHG1*     KIAA1209 protein                                                                                                             AI301815
  6      108691   *ACK1*        Activated p21cdc42Hs kinase                                                                                                  AA427891
  7      107840   *EPC1*        ESTs                                                                                                                         AA120875
  8      126868   *TMC4*        DKFZP586J0619 protein                                                                                                        AA991211
  9      106257   *FLJ32499*    *H. sapiens*cDNA FLJ12749 fis, clone NT2RP2001149                                                                            W56590
  10     128493   *GMFG*        Glia maturation factor, gamma                                                                                                AI311932
  11     128702                                                                                                                                              AI313031
  12     129547   *METAP2*      Methionine aminopeptidase; eIF-2-associated p67                                                                              AA283030
  13     111787   *ZNF451*      *H. sapiens*cDNA FLJ13010 fis, clone NT2RP3000542                                                                            AA486412
  14     103209   *RBMS1*       *H. sapiens*mRNA; cDNA DKFZp564H0764 (from clone DKFZp564H0764)                                                              R62566
  15     108595   *CCL19*       Small inducible cytokine subfamily A (Cys-Cys), member 19                                                                    AA680186
  16     129267                                                                                                                                              AA609203
  17     109127   *ESR1*        Oestrogen receptor 1                                                                                                         AA291749
  18     100263   *MYB*         V-myb avian myeloblastosis viral oncogene homolog                                                                            N49284
  19     100524   *CELSR2*      Cadherin, EGF LAG seven-pass G-type receptor 2, flamingo (Drosophila) homolog                                                H39187
  20     100260   *MAL*         Mal, T-cell differentiation protein                                                                                          AA227885
  21     102995   *PIGT*        CGI-06 protein                                                                                                               H82992
  22     108649                 Human clone 23948 mRNA sequence                                                                                              H15114
  23     109246   *BCL2*        B-cell CLL/lymphoma 2                                                                                                        W63749
  24     100203   *TNFAIP3*     Tumour necrosis factor, alpha-induced protein 3                                                                              AA476272
  25     107809   *XBP1*        X-box binding protein 1                                                                                                      W90128
  26     102921                 *H. sapiens*mRNA; cDNA DKFZp434D0818 (from clone DKFZp434D0818)                                                              N95578
  27     108671   *BCAT2*       Branched chain aminotransferase 2, mitochondrial                                                                             AA436410
  28     101925   *EZH2*                                                                                                                                     AA430744
  29     123382   *HIG1*        Likely ortholog of mouse hypoxia induced gene 1                                                                              T74105
  30     131187   *KPNA2*       Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)                                                                         AA489087
  31     111288                 *H. sapiens*mRNA; cDNA DKFZp564C2063 (from clone DKFZp564C2063)                                                              AA416628
  32     109170   *C4A*         Complement component 4A                                                                                                      AA664406
  33     108203   *TEGT*        Testis enhanced gene transcript (BAX inhibitor 1)                                                                            AA629591
  34     102639   *EML2*        Microtubule-associated protein like echinoderm EMAP                                                                          R27580
  35     131258   *PSMA7*       Proteasome (prosome, macropain) subunit, alpha type, 7                                                                       AI318565
  36     123478   *FLJ14712*    Hypothetical protein FLJ14712                                                                                                N79050
  37     109415   *FCGBP*       Fc fragment of IgG binding protein                                                                                           R52030
  38     127815   *PLAT*        Plasminogen activator, tissue                                                                                                R38933
  39     115769                 ESTs                                                                                                                         AA406313
  40     106220   *GIMAP5*      Hypothetical protein FLJ11296                                                                                                AA150443
  41     128641   *PTTG1*       Pituitary tumour-transforming 1                                                                                              AI362866
  42     105439   *TGOLN2*      Trans-Golgi network protein (46-, 48-, 51-kD isoforms)                                                                       T81338
  43     101362   *ERBB2*       V-erb-b2 avian erythroblastic leukaemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog)               AA446928
  44     108387   *IDH2*        Isocitrate dehydrogenase 2 (NADP+), mitochondrial                                                                            AA679907
  45     100352   *TGOLN2*      Trans-Golgi network protein (46-, 48-, 51-kD isoforms)                                                                       H82891
  46     107941   *PLAC8*       Hypothetical protein                                                                                                         AA150263
  47     100104   *SELL*        Selectin L (lymphocyte adhesion molecule 1)                                                                                  H00662
  48     110983   *DLEU1*       Deleted in lymphocytic leukaemia, 1                                                                                          AA425755
  49     108438   *GRB7*        Growth factor receptor-bound protein 7                                                                                       H53703
  50     107752   *PAG*         Phosphoprotein associated with GEMs                                                                                          N50114
  51     128532   *LTB*         Lymphotoxin beta (TNF superfamily, member 3)                                                                                 AI351740
  52     124620   *ASTN2*       KIAA0634 protein                                                                                                             AA404602
  53     102357   *CHN1*        Chimerin (chimaerin) 1                                                                                                       AA598668
  54     109454   *AKR7A2*      Aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase)                                                       T62865
  55     108678   *CASP10*      Caspase 10, apoptosis-related cysteine protease                                                                              H80712
  56     131111   *CUGBP2*      CUG triplet repeat, RNA-binding protein 2                                                                                    AA047257
  57     123475   *C9orf87*     Hypothetical protein FLJ10493                                                                                                N53432
  58     105013                 EST                                                                                                                          H61003
  59     100791   *TDG*         Thymine-DNA glycosylase                                                                                                      AA496947
  60     100528   *BCL2L2*      BCL2-like 2                                                                                                                  AA454588
  61     116312   *FLJ14299*    Hypothetical protein FLJ14299                                                                                                AA453170
  62     100700   *TRIB2*       GS3955 protein                                                                                                               AA458653
  63     102004   *PIK3R1*      Phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)                                                     R54050
  64     104569   *MYO1B*       *H. sapiens*cDNA FLJ20153 fis, clone COL08656, highly similar to AJ001381 *H. sapiens*incomplete cDNA for a mutated allele   N95358
  65     113907   *SNRPB2*      Small nuclear ribonucleoprotein polypeptide B\"                                                                              H00286
  66     128683   *WASL*        Wiskott-Aldrich syndrome-like                                                                                                AI261600
  67     123768   *DUSP22*      Mitogen-activated protein kinase phosphatase x                                                                               H42417
  68     105099   *RET*         Ret proto-oncogene (multiple endocrine neoplasia MEN2A, MEN2B and medullary thyroid carcinoma 1, Hirschsprung disease)       H24956
  69     116859   *STMN1*       Leukaemia-associated phosphoprotein p18 (stathmin)                                                                           AA873060
  70     111660   *FLJ13710*    ESTs                                                                                                                         AA120866
  71     100112   *SAA1*        Serum amyloid A1                                                                                                             H25546
  72     100840   *THOC1*       Nuclear matrix protein p84                                                                                                   AA129297
  73     129239                 EST, Moderately similar to AF119917 63 PRO2831 \[*H. sapiens*\]                                                              W95750
  74     115662   *GIMAP4*      Hypothetical protein FLJ11110                                                                                                AA406363
  75     109607   *HTPAP*       ESTs                                                                                                                         T48412
  76     108692   *EMP2*        Epithelial membrane protein 2                                                                                                T88721
  77     105133   *JUNB*        Jun B proto-oncogene                                                                                                         N94468
  78     129959   *LOC283352*   EST                                                                                                                          AI023540

DCIS, ductal carcinoma *in situ*; EST, expressed sequence tag; NKI ID, Netherlands Cancer Institute (Amsterdam, The Netherlands) identification number.
